You are here

Share:

Small-Molecule Inhibitors of Angiogenesis

Summary
The National Cancer Institute's Angiogenesis Core Facility seek parties interested in in-licensing a new set of non-cytotoxic antiangiogenic small molecules.
NIH Reference Number
E-263-2009
Product Type
Keywords
  • antiangiogenic
  • Angiogenesis
  • age-related macular degeneration, diabetic retinopathy, endometriosis
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

The National Cancer Institute's Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a new set of non-cytotoxic antiangiogenic small molecules. 

Angiogenesis, the growth of new blood vessels from existing vessels, is a normal and vital process in growth and development.  Deregulation of angiogenesis plays a role in many human diseases, including cancer, age-related macular degeneration, diabetic retinopathy, and endometriosis.

NCI investigators have used a cell-based high-throughput screening method to identify a set of anti-angiogenic small molecules.  These compounds are highly active, inhibiting both endothelial cell growth and tube formation, and are not cytotoxic.  Structure-activity relationship analysis has revealed that these compounds are unrelated to known anti-angiogenic compounds, and hence may operate through a novel mechanism of action.  Thus, these compounds would be promising candidates for the development of new anti-angiogenesis therapeutics.

Potential Commercial Applications
  • Development of new anti-angiogenesis therapeutics.
Competitive Advantages
  • These compounds are structurally unrelated to other known anti-angiogenesis compounds, and exhibit high activity without cytotoxicity.
Inventor(s)

Enrique Zudaire Ubani (NCI), Frank Cuttitta (NCI), Marta Aparico (NCI)

Development Stage
Patent Status
  • U.S. Patent Issued: U.S. Patent Number 9186365, Issued 17 Nov 2015
  • Foreign Issued: JP - Patent Number 5886743, Issued 19 Feb 2016
Related Technologies
Therapeutic Area
Updated
Friday, May 4, 2018